Food

 

New Study: Metastatic Colorectal Cancer - Pipeline Review, H1 2015



25.08.2015 20:25:19 - Fast Market Research recommends "Metastatic Colorectal Cancer - Pipeline Review, H1 2015" from Global Markets Direct, now available

(live-PR.com) - Global Markets Direct's, 'Metastatic Colorectal Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Colorectal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,

 

and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Full Report Details at
- www.fastmr.com/prod/1038132_metastatic_colorecta ..

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
* The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
* The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects
* The report summarizes all the dormant and discontinued pipeline projects
* A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
* Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
* A detailed assessment of monotherapy and combination therapy pipeline projects
* Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
* Latest news and deals relating related to pipeline products

Reasons to Get this Report

* Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
* Develop strategic initiatives by understanding the focus areas of leading companies
* Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
* Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
* Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: AB Science, AbbVie Inc., Actinium Pharmaceuticals, Inc., Advenchen Laboratories, LLC, Alchemia Limited, Allinky Biopharma, Amgen Inc., Angiogene Pharmaceuticals Limited, Array BioPharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bavarian Nordic A/S, Bayer AG, Biocon Limited, Biothera, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Inc., Cellular Biomedicine Group, Inc., Cornerstone Pharmaceuticals, Inc., CureTech Ltd., DanDrit Biotech A/S, Eisai Co., Ltd., Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Etubics Corporation, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genor BioPharma Co., Ltd., Glycotope GmbH, Hospira, Inc., Hutchison MediPharma Limited, Ignyta, Inc., immatics biotechnologies GmbH, Immodulon Therapeutics Ltd., Immunomedics, Inc., Immunovative Therapies, Ltd., Inbiopro Solutions Pvt. Ltd., Incyte Corporation, Kadmon Corporation, LLC, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., Mabion SA, MacroGenics, Inc., MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., MolMed S.p.A., Mologen AG, Morphotek, Inc., Nektar Therapeutics, Nippon Kayaku Co., Ltd., Novartis AG, Oncobiologics, Inc., Oncolytics Biotech Inc., Otsuka Holdings Co., Ltd., Panacea Biotec Limited, Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Precision Biologics, Inc., PsiOxus Therapeutics Limited, Regeneron Pharmaceuticals, Inc., Simcere Pharmaceutical Group, Symphogen A/S, Syndax Pharmaceuticals, Inc., TetraLogic Pharmaceuticals

Browse our complete collection of Pharmaceuticals research reports at www.fastmr.com/catalog/browse.aspx?category=16&a ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)


Author:
Bill Thompson
e-mail
Web: http://www.fastmr.com
Phone: 1.413.485.7001


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us